Still, some PPARγ agonists may have off-target effects, such as PPAR-independent genomic actions or non-genomic actions controlled by post-translational modifications [35,36,37], or may have entirely novel activities in combination with imatinib (a BCR-ABL tyrosine kinase inhibitor) or MEK inhibitors in cancer treatment [38,39,40]. This evidence concerns the gene ABL1 and cancer.